These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 8606641

  • 1. Effects of acipimox, an antilipolytic drug, on the growth hormone (GH) response to GH-releasing hormone alone or combined with arginine in obesity.
    Maccario M, Procopio M, Grottoli S, Oleandri SE, Boffano GM, Taliano M, Camanni F, Ghigo E.
    Metabolism; 1996 Mar; 45(3):342-6. PubMed ID: 8606641
    [Abstract] [Full Text] [Related]

  • 2. Long-term administration of acipimox potentiates growth hormone response to growth hormone-releasing hormone by decreasing serum free fatty acid in obesity.
    Nam SY, Lee, Kim KR, Lee HC, Nam MS, Cho JH, Huh KB.
    Metabolism; 1996 May; 45(5):594-7. PubMed ID: 8622602
    [Abstract] [Full Text] [Related]

  • 3. Acipimox potentiates growth hormone (GH) response to GH-releasing hormone with or without pyridostigmine by lowering serum free fatty acid in normal and obese subjects.
    Lee EJ, Nam SY, Kim KR, Lee HC, Cho JH, Nam MS, Song YD, Lim SK, Huh KB.
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2495-8. PubMed ID: 7629249
    [Abstract] [Full Text] [Related]

  • 4. Effect of acute pharmacological reduction of plasma free fatty acids on growth hormone (GH) releasing hormone-induced GH secretion in obese adults with and without hypopituitarism.
    Cordido F, Fernandez T, Martinez T, Peñalva A, Peinó R, Casanueva FF, Dieguez C.
    J Clin Endocrinol Metab; 1998 Dec; 83(12):4350-4. PubMed ID: 9851776
    [Abstract] [Full Text] [Related]

  • 5. Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression.
    Cordido F, Peino R, Peñalva A, Alvarez CV, Casanueva FF, Dieguez C.
    J Clin Endocrinol Metab; 1996 Mar; 81(3):914-8. PubMed ID: 8772550
    [Abstract] [Full Text] [Related]

  • 6. Short-term fasting in obesity fails to restore the blunted GH responsiveness to GH-releasing hormone alone or combined with arginine.
    Procopio M, Maccario M, Grottoli S, Oleandri SE, Boffano GM, Camanni F, Ghigo E.
    Clin Endocrinol (Oxf); 1995 Dec; 43(6):665-9. PubMed ID: 8736266
    [Abstract] [Full Text] [Related]

  • 7. Elevated insulin levels contribute to the reduced growth hormone (GH) response to GH-releasing hormone in obese subjects.
    Lanzi R, Luzi L, Caumo A, Andreotti AC, Manzoni MF, Malighetti ME, Sereni LP, Pontiroli AE.
    Metabolism; 1999 Sep; 48(9):1152-6. PubMed ID: 10484056
    [Abstract] [Full Text] [Related]

  • 8. Acipimox-mediated plasma free fatty acid depression per se stimulates growth hormone (GH) secretion in normal subjects and potentiates the response to other GH-releasing stimuli.
    Peino R, Cordido F, Peñalva A, Alvarez CV, Dieguez C, Casanueva FF.
    J Clin Endocrinol Metab; 1996 Mar; 81(3):909-13. PubMed ID: 8772549
    [Abstract] [Full Text] [Related]

  • 9. Acipimox potentiates growth hormone response to growth hormone-releasing hormone by decreasing serum free fatty acid levels in hyperthyroidism.
    Lee EJ, Kim KR, Lee HC, Cho JH, Nam MS, Nam SY, Song YD, Lim SK, Huh KB.
    Metabolism; 1995 Nov; 44(11):1509-12. PubMed ID: 7476342
    [Abstract] [Full Text] [Related]

  • 10. Restoration of growth hormone (GH) response to GH-releasing hormone in elderly and obese subjects by acute pharmacological reduction of plasma free fatty acids.
    Pontiroli AE, Manzoni MF, Malighetti ME, Lanzi R.
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3998-4001. PubMed ID: 8923850
    [Abstract] [Full Text] [Related]

  • 11. Effect of acute reduction of free fatty acids by acipimox on growth hormone-releasing hormone-induced GH secretion in type 1 diabetic patients.
    Alvarez P, Isidro L, Peinó R, Leal-Cerro A, Casanueva FF, Dieguez C, Cordido F.
    Clin Endocrinol (Oxf); 2003 Oct; 59(4):431-6. PubMed ID: 14510904
    [Abstract] [Full Text] [Related]

  • 12. Acute pharmacological reduction of plasma free fatty acids enhances the growth hormone (GH)-releasing hormone-mediated GH secretion in patients with Cushing's syndrome.
    Leal-Cerro A, Jimenez LM, Astorga R, Fernandez-Lopez I, Dieguez C, Casanueva FF.
    J Clin Endocrinol Metab; 1997 Sep; 82(9):3165-8. PubMed ID: 9284763
    [Abstract] [Full Text] [Related]

  • 13. In obesity, glucose load loses its early inhibitory, but maintains its late stimulatory, effect on somatotrope secretion.
    Grottoli S, Procopio M, Maccario M, Zini M, Oleandri SE, Tassone F, Valcavi R, Ghigo E.
    J Clin Endocrinol Metab; 1997 Jul; 82(7):2261-5. PubMed ID: 9215304
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Evidence for an inhibitory effect of physiological levels of insulin on the growth hormone (GH) response to GH-releasing hormone in healthy subjects.
    Lanzi R, Manzoni MF, Andreotti AC, Malighetti ME, Bianchi E, Sereni LP, Caumo A, Luzi L, Pontiroli AE.
    J Clin Endocrinol Metab; 1997 Jul; 82(7):2239-43. PubMed ID: 9215300
    [Abstract] [Full Text] [Related]

  • 18. Growth hormone (GH) autofeedback on GH response to GH-releasing hormone. Role of free fatty acids and somatostatin.
    Pontiroli AE, Lanzi R, Monti LD, Sandoli E, Pozza G.
    J Clin Endocrinol Metab; 1991 Feb; 72(2):492-5. PubMed ID: 1671389
    [Abstract] [Full Text] [Related]

  • 19. Effect of arginine and pyridostigmine on the GHRH-induced GH rise in obesity and Cushing's syndrome.
    Procopio M, Invitti C, Maccario M, Grottoli S, Cavagnini F, Camanni F, Ghigo E.
    Int J Obes Relat Metab Disord; 1995 Feb; 19(2):108-12. PubMed ID: 7735336
    [Abstract] [Full Text] [Related]

  • 20. GH response to GHRH combined with pyridostigmine or arginine in different conditions of low somatotrope secretion in adulthood: obesity and Cushing's syndrome in comparison with hypopituitarism.
    Procopio M, Maccario M, Savio P, Valetto MR, Aimaretti G, Grottoli S, Oleandri SE, Baffoni C, Tassone F, Arvat E, Camanni F, Ghigo E.
    Panminerva Med; 1998 Mar; 40(1):13-7. PubMed ID: 9573747
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.